Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-112821
Filing Date
2025-11-14
Accepted
2025-11-14 19:58:46
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7487
  Complete submission text file 0001104659-25-112821.txt   9448
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-37761 | Film No.: 251488965
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address THEATERSTRASSE 12 ZURICH Switzerland CH-8001
Business Address THEATERSTRASSE 12 ZURICH Switzerland CH-8001 41 44 267 67 77
Bellevue Group AG (Filed by) CIK: 0001674546 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SCHEDULE 13G